BioGrip

Market position

Described in Mexican and Latin American coverage as a notable regional player in bionics and health technology, and as the only Latin American startup in its Techstars Boston cohort. It positions itself as a control-system and interface provider rather than solely a prosthetics maker.

The company contrasts its approach with traditional prosthetics that rely on pre-programmed commands or manual inputs, citing thought-driven, intuitive control with a reduced learning curve, independent finger movement without direct neural connections, and an ergonomic design intended to counter the high rate of prosthesis abandonment. Its user-centered development with early patients, and an emphasis on affordability and accessibility, are presented as further distinguishing factors. Current materials emphasize non-invasive, anatomy-adaptive high-density sensing with per-user AI calibration.

Technology

A non-invasive human–machine interface that captures bioelectric and neuromuscular signals from the skin and processes them with artificial intelligence and deep learning to infer intended movement. The product architecture comprises Synaptic Mesh, an anatomy-adaptive high-density sensing interface designed to maximize signal quality and coverage, and Synaptic Cortex, an adaptive AI engine that calibrates per user by identifying the most informative signals and decodes independent neuromuscular activity to support dexterous, coordinated and simultaneous control. The bionic arm combines mechanics, electronics and AI and enables independent finger movement without direct neural connections. A separate wireless nerve–machine system targets post-surgical rehabilitation.

Go-to-market

BioGrip works closely with early patients it calls "ambassadors," who contribute their perspective and needs to device development, and collaborates with physicians and orthopedists on fit and functionality. It has used startup competitions, accelerators and global events for visibility and investor access, including Techstars Boston, the Entrepreneurship World Cup, INCmty, and the Santander X Global Challenge. The company states it is actively testing and integrating its technology with real-world partners and solicits collaborators, partners and participants through its site.

People with upper-limb amputations, whether from accident or congenital causes; patients recovering from severe peripheral nerve injury or limb transplant surgery; and, more broadly, individuals with mobility impairments. The technology is also positioned for intelligent robotics and human-augmentation applications.

Geography

Mexico-based, with ties to Tecnológico de Monterrey's Chihuahua campus, where co-founder Alan Hernández is a professor and graduate. The company participated in a three-month accelerator in Boston, United States, in 2024 and has presented at events in Saudi Arabia and Rio de Janeiro, Brazil. Its current site lists the corporate entity as Synaptic Bionics, Inc.

History

One account dates the company's start to 2019 as an effort to address prosthesis abandonment in Mexico. BioGrip began by addressing upper-limb amputation with bionic arms and subsequently positioned itself around the underlying control system and interface. It won the INC Accelerator at INCmty in 2022 and the best technology award at the 2022 Entrepreneurship World Cup in Saudi Arabia. After three years of research and four prototypes it began evaluating market entry. Following an application process started in 2023, it was accepted into the Techstars Boston Accelerator, which ran for three months from March 2024, where it was described as the only Latin American startup among 12 participants. It was later selected from more than 280 startups across 16 countries to represent Mexico and Latin America at a global event in Rio de Janeiro. The company's current website presents the technology under the Synaptic Pulse brand, stated to be a property of Synaptic Bionics, Inc.

Risks & controversies

Coverage notes that roughly 90% of patients in Mexico abandon conventional prostheses due to discomfort or lack of functionality, the problem the company is addressing, and that as of the reporting it was still evaluating how to enter the market after the prototype stage. Founding-year information is inconsistent across sources, and the company's current web presence uses a different brand and corporate name than the BioGrip identity used in earlier coverage.